Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients
Journal of Neuroimmunology, ISSN: 0165-5728, Vol: 84, Issue: 2, Page: 213-217
1998
- 8Citations
- 15Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- CrossRef7
- Captures15
- Readers15
- 15
Article Description
The time-course of CD25 (the 55-kD/ α subunit of the interleukin-2 (IL-2) receptor) expression on CD4+ T lymphocytes, and serum levels of soluble IL-2 receptors (sIL-2R) and IL-2 were evaluated in relapsing–remitting multiple sclerosis (RRMS) patients treated with interferon beta-1b (IFN β 1b). Peripheral blood samples were collected before therapy (T0), and 1 (T1), 2 (T2), 3 (T3), 6 (T4), and 12 (T5) months after therapy initiation. While at T1 and T2, half the patients showed an increased number of circulating CD4+CD25+ lymphocytes and an up-regulation of CD25 expression, at T3 this T-cell subset was significantly reduced in all the patients. From T4 to T5, however, the progressive return to pretreatment values was observed. Serum sIL-2R levels were not significantly affected by IFN β 1b at any time point. IL-2 was detected in only a few patients at T0, and never at T1 to T5. The transient up-regulation of CD25+ expression that occurred in about 50% of the patients may explain the unchanged relapse rate observed during the first 2 to 3 months after starting IFN β 1b therapy. Our study demonstrates that IFN β 1b down-regulates CD25 expression in vivo. This effect, however, was observed only after 3 months of therapy, and was followed by the return to pretreatment values after 6 to 12 months. Taken all together, our findings suggest that IFN β 1b only transiently affects CD25 expression in vivo, and that this effect cannot account for the reported long-lasting beneficial action of IFN β 1b on RRMS.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0165572897002592; http://dx.doi.org/10.1016/s0165-5728(97)00259-2; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032522276&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/9628465; http://linkinghub.elsevier.com/retrieve/pii/S0165572897002592; http://api.elsevier.com/content/article/PII:S0165572897002592?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0165572897002592?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0165572897002592; http://dx.doi.org/10.1016/s0165-5728%2897%2900259-2; https://dx.doi.org/10.1016/s0165-5728%2897%2900259-2
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know